Related references
Note: Only part of the references are listed.The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)
Stacy L. Moulder et al.
CLINICAL CANCER RESEARCH (2017)
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
Richard Marcotte et al.
CELL (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
2016 update of the PRIDE database and its related tools (vol 44, pg D447, 2016)
Juan Antonio Vizcaino et al.
NUCLEIC ACIDS RESEARCH (2016)
Early signaling dynamics of the epidermal growth factor receptor
Raven J. Reddy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: Opportunities for signaling-adapted therapies
Anne Hansen Ree et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Empirical inference of circuitry and plasticity in a kinase signaling network
Edmund H. Wilkes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
Timothy J. Stuhlmiller et al.
CELL REPORTS (2015)
Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer
B. L. Allen-Petersen et al.
ONCOGENE (2014)
FAK in cancer: mechanistic findings and clinical applications
Florian J. Sulzmaier et al.
NATURE REVIEWS CANCER (2014)
Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells via Binding to the Extracellular Domain of HER2
Christian Jost et al.
STRUCTURE (2013)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Richard Marcotte et al.
CANCER DISCOVERY (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
DESIGNED ANKYRIN REPEAT PROTEINS (DARPINS): FROM RESEARCH TO THERAPY
Rastislav Tamaskovic et al.
METHODS IN ENZYMOLOGY: PROTEIN ENGINEERING FOR THERAPEUTICS, VOL 203, PT B (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection
Yu Xue et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
GLay: community structure analysis of biological networks
Gang Su et al.
BIOINFORMATICS (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver
Dhara N. Amin et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery
Arend H. Sikkema et al.
CANCER RESEARCH (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Phosphoproteomic analysis of Her2/neu signaling and inhibition
Ron Bose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
XF Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Kinases: positive and negative regulators of apoptosis
RA Franklin et al.
LEUKEMIA (2000)
Share Paper
